Nature communications · 2026
Phytic acid (InsP6) activates HDAC3 epigenetic axis to maintain intestinal barrier function.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chatterjee Sujan, Sin Zachary, Tran Nguyen, Vierra Loretta, Shukla Anuj, Tran Tam, Koshkaryan George, Ritter Kevin, Su Xue Bessie, Ragsac Saharat Jolak, Park Seungman, Liu Qian, Van Richard, Huang Katherine, Huff-Hardy Kayci, Rood Richard, Gremida Anas, Gregory Martin, Chen Chien-Huan, Han Mira V, Deepak Parakkal, Saiardi Adolfo, Jessen Henning J, Guha Prasun
Аннотация
HDAC inhibition shows promise in cancer treatment but pan-HDAC inhibitors cause gastrointestinal issues in 48% of patients. Understanding HDAC activation mechanisms is crucial to treating diverse diseases beyond cancer. Our study reveals that inositol polyphosphate multikinase (IPMK) and inositol hexakisphosphate (InsP6 or phytic acid), enriched in vegan diets, play essential roles in activating the HDAC3 epigenetic axis and maintaining intestinal barrier integrity. IPMK binds to HDAC3 and drives InsP6 synthesis, which selectively activates HDAC3 at a 10 nM concentration by recruiting the DAD domain of its corepressor protein. IPMK deletion diminishes HDAC3 activation, leading to histone hyperacetylation and MMP gene transcription that compromise intestinal barrier integrity. InsP6 treatment is sufficient to rescue these effects. In inflammatory bowel disease, diminished IPMK levels exacerbate intestinal permeability, while oral InsP6 treatment mitigates leaky gut effects by restoring the HDAC3 epigenetic axis, highlighting the clinical significance of the IPMK-HDAC3 pathway and the therapeutic potential of phytic acid.